Italian NanoPhoria Bioscience raises surprisingly high €83.5 million to advance novel heart failure therapy with a very early non clinical asset.
ADVERTISEMENT
Tag Archive for: heart failure
Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure.